Table 4.

Mini-Mental State Examination Level of Impairment Across Follow-up Visits

Level of Impairment	Total (N = 79)	VACV (n = 36)	Placebo (n = 43)	P Value*
Baseline: begin study drug
Moderate/severe/very severe (<23)	26 (34.7)	12 (35.3)	14 (34.1)
No/mild (23–30)	49 (65.3)	22 (64.7)	27 (65.9)
Day 90: complete study drug
Moderate/severe/very severe (<23)	8 (11.9)	3 (9.7)	5 (13.9)	.72
No/mild (23–30)	59 (88.1)	28 (90.3)	31 (86.1)
6 mo
Moderate/severe/very severe (<23)	8 (13.1)	4 (14.3)	4 (12.1)	NS
No/mild (23–30)	53 (86.9)	24 (85.7)	29 (87.9)
12 mo
Moderate/severe/very severe (<23)	9 (13.2)	4 (12.1)	5 (14.3)	NS
No/mild (23–30)	59 (86.8)	29 (87.9)	30 (85.7)
24 mo
Moderate/severe/very severe (<23)	6 (9.1)	4 (12.5)	2 (5.9)	.42
No/mild (23–30)	60 (90.9)	28 (87.5)	32 (94.1)

Data are presented as No. (%).

Abbreviations: NS, nonsignificant; VACV, valacyclovir.

* P value by Fisher exact test for categorical data.